Jan Lehmann

4.2k total citations
81 papers, 2.8k citations indexed

About

Jan Lehmann is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jan Lehmann has authored 81 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Surgery, 25 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Jan Lehmann's work include Bladder and Urothelial Cancer Treatments (40 papers), Urinary and Genital Oncology Studies (32 papers) and Prostate Cancer Treatment and Research (10 papers). Jan Lehmann is often cited by papers focused on Bladder and Urothelial Cancer Treatments (40 papers), Urinary and Genital Oncology Studies (32 papers) and Prostate Cancer Treatment and Research (10 papers). Jan Lehmann collaborates with scholars based in Germany, United States and Switzerland. Jan Lehmann's co-authors include Michael Stöckle, Margitta Retz, Bernd Wullich, H. Suttmann, Friedrich Paulsen, Jürgen Harder, Jörn Kamradt, Stefan Siemer, Peter Albers and Axel Heidenreich and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Jan Lehmann

79 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Lehmann Germany 30 1.5k 826 704 469 391 81 2.8k
Rodrigue Mortel United States 38 939 0.6× 526 0.6× 348 0.5× 1.1k 2.4× 50 0.1× 122 4.6k
Hetal Patel United Kingdom 19 217 0.1× 488 0.6× 315 0.4× 120 0.3× 94 0.2× 47 1.7k
Bhavna Kumar United States 32 761 0.5× 1.6k 1.9× 427 0.6× 1.4k 3.1× 30 0.1× 65 3.7k
Angel Chao Taiwan 35 689 0.4× 986 1.2× 327 0.5× 526 1.1× 13 0.0× 184 3.7k
Peyton T. Taylor United States 29 673 0.4× 262 0.3× 198 0.3× 597 1.3× 35 0.1× 72 2.2k
Nancy Wehner United States 22 138 0.1× 428 0.5× 780 1.1× 224 0.5× 230 0.6× 37 2.0k
C. H. Buckley United Kingdom 34 526 0.3× 474 0.6× 198 0.3× 541 1.2× 29 0.1× 106 3.1k
David Cantú de León Mexico 28 401 0.3× 1.1k 1.4× 231 0.3× 470 1.0× 11 0.0× 146 2.5k
John Chester United Kingdom 30 599 0.4× 1.2k 1.4× 295 0.4× 1.2k 2.5× 81 0.2× 83 2.8k
Stephen C.-T. Lam United States 29 208 0.1× 2.3k 2.8× 389 0.6× 193 0.4× 53 0.1× 37 4.1k

Countries citing papers authored by Jan Lehmann

Since Specialization
Citations

This map shows the geographic impact of Jan Lehmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Lehmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Lehmann more than expected).

Fields of papers citing papers by Jan Lehmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Lehmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Lehmann. The network helps show where Jan Lehmann may publish in the future.

Co-authorship network of co-authors of Jan Lehmann

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Lehmann. A scholar is included among the top collaborators of Jan Lehmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Lehmann. Jan Lehmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heinzelbecker, Julia, et al.. (2024). Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type. Journal of Cancer Survivorship. 19(5). 1651–1665.
2.
Krämer, H., et al.. (2018). Gibt’s auch ’nen Frauenarzt für Männer?: Eine randomisiert kontrollierte Studie der ÄGGF-Präventionsveranstaltungen in Schulen als Brücke zur Jungensprechstunde beim Urologen. Urologe A. 57(10). 1230–1239. 1 indexed citations
3.
4.
Keck, Bastian, Sven Wach, Peter J. Goebell, et al.. (2013). SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. Annals of Surgical Oncology. 20(11). 3669–3674. 10 indexed citations
5.
Keck, Bastian, Sven Wach, Robert Stoehr, et al.. (2013). Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer. 13(1). 71–71. 57 indexed citations
6.
Nordentoft, Iver, Lars Dyrskjøt, Julie Støve Bødker, et al.. (2011). Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer. BMC Cancer. 11(1). 135–135. 30 indexed citations
7.
Smith, Steven C., Alexander S. Baras, Garrett M. Dancik, et al.. (2011). A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. The Lancet Oncology. 12(2). 137–143. 100 indexed citations
8.
Hoffmann, Andreas-Claudius, Peter J. Wild, Simone Bertz, et al.. (2010). MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy. Neoplasia. 12(8). 628–636. 106 indexed citations
9.
10.
Keck, Bastian, Robert Stoehr, Sven Wach, et al.. (2010). The plasmacytoid carcinoma of the bladder—rare variant of aggressive urothelial carcinoma. International Journal of Cancer. 129(2). 346–354. 80 indexed citations
11.
Suttmann, H., Aleksandar Grgic, Jan Lehmann, et al.. (2008). Combining 153 Sm-Lexidronam and Docetaxel for the Treatment of Patients with Hormone-Refractory Prostate Cancer: First Experience. Cancer Biotherapy and Radiopharmaceuticals. 23(5). 609–618. 15 indexed citations
12.
Wit, Maike de, Winfried Brenner, Michael Hartmann, et al.. (2008). [18F]-FDG–PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Annals of Oncology. 19(9). 1619–1623. 55 indexed citations
13.
Suttmann, H., Margitta Retz, Friedrich Paulsen, et al.. (2008). Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urology. 8(1). 5–5. 146 indexed citations
14.
Maase, Hans von der, Jan Lehmann, Gwénaëlle Gravis, et al.. (2006). A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Annals of Oncology. 17(10). 1533–1538. 40 indexed citations
15.
Lehmann, Jan, H. Suttmann, Markus Hack, et al.. (2006). Transitional Cell Carcinoma of the Ureter: Prognostic Factors Influencing Progression and Survival. European Urology. 51(5). 1281–1288. 67 indexed citations
16.
Lehmann, Jan, Margitta Retz, Sukhvinder Sidhu, et al.. (2006). Antitumor Activity of the Antimicrobial Peptide Magainin II against Bladder Cancer Cell Lines. European Urology. 50(1). 141–147. 180 indexed citations
17.
Retz, Margitta, Sukhvinder Sidhu, Ekaterina Blaveri, et al.. (2004). CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. International Journal of Cancer. 114(2). 182–189. 65 indexed citations
18.
Lehmann, Jan, et al.. (2003). Systemische Chemotherapie des Urothelkarzinoms. Oncology Research and Treatment. 26(4). 18–25. 2 indexed citations
19.
Paulsen, Friedrich, Thomas Pufe, U. Schaudig, et al.. (2002). Protection of Human Efferent Tear Ducts by Antimicrobial Peptides. Advances in experimental medicine and biology. 506(Pt A). 547–553. 17 indexed citations
20.
Lehmann, Jan, Margitta Retz, & Michael Stöckle. (2002). Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. World Journal of Urology. 20(3). 144–150. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rodrigue Mortel Breakdown of academic impact, for papers by Hetal Patel Breakdown of academic impact, for papers by Bhavna Kumar Breakdown of academic impact, for papers by Angel Chao Breakdown of academic impact, for papers by Peyton T. Taylor Breakdown of academic impact, for papers by Nancy Wehner Breakdown of academic impact, for papers by C. H. Buckley Breakdown of academic impact, for papers by David Cantú de León Breakdown of academic impact, for papers by John Chester Breakdown of academic impact, for papers by Stephen C.-T. Lam
Rankless by CCL
2026